genprowebdirectory
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Genetic Disease Testing
Multiomics Approach Improves Diagnosis of Rare Disease, Methylmalonic Aciduria
Base Editing
Zinc Finger Design AI Tool Opens Door to Large-Scale Gene Therapies
Cancer
Multidrug Nanoparticle Platform Improves Drug Delivery against Cancer
Cancer
Cancer’s Capacity to Resist Treatment Thwarted
Animal Models
Microbiome and its Metabolites Promote Endometriosis in Animal Model
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
Artificial Intelligence
Chiral Spectroscopy Lessens the Chiral Resolution Stumbling Block
Antibodies
Advanced Therapies Could Be Sleepwalking into a Manufacturing Cost Crisis
Bioprocessing
Cell and Gene Therapy Scale-Up Challenges
Bioprocessing
Making Molecules Instead of Growing Them
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Home
Neurological Disorders
ALS
ALS
ALS
Alzheimers
Mental Health Disorders
Parkinsons
Schizophrenia
Most popular
Latest
Featured posts
Most popular
7 days popular
By review score
Random
ALS
Sanofi, Denali Launch $1B+ Alliance to Develop RIPK1 Inhibitors for Neurological, Inflammatory Diseases
ALS
Amyloids Shown to Also Play Beneficial Role in Developing Healthy Muscle Tissue
ALS
Five Life Sciences Researchers Win Breakthrough Prizes Totaling $15M
ALS
Studying Changing Neuron Size May Lead to New Therapies for Motor Neuron Disease
ALS
Size Matters: Study Reveals “Brain Reserve” Genes
ALS
CRISPR Screen Identifies Genetic Modifiers of ALS
ALS
Hope for ALS Patients Comes from New Understanding of RNA Metabolism...
ALS
Hardening of the RNA Condensates May Solidify Neurodegeneration
ALS
Novel Research Model Offers Hope to ALS and MS Patients
ALS
Biogen, Ionis Launch $1B+ Expanded Neuro Drug Partnership, following Spinraza Success
ALS
Neuraltus Weighs Future of Lead Candidate NP001 after Failure in Phase...
ALS
Flex Pharma Axes 60% of Workforce, Explores Sale after Halting Phase...
ALS
Sangamo, Pfizer Partner on Gene Therapy for ALS, FTLD
ALS
Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders
ALS
Proteomics Finding May Lead to Therapy Targeted at Cellular Pathway Linked...
1
2
3
4
Page 1 of 4
Scroll Up
Login
Subscribe
![The hnRNP A1B is expressed in the central nervous system and forms cytoplasmic aggregates in ALS patient neurons. [CRCHUM]](https://www.genengnews.com/wp-content/uploads/2018/08/Mar19_2018_CRCHUM_hnRNPA1B2262381965-324x160.jpg "Hope for ALS Patients Comes from New Understanding of RNA Metabolism Misregulation")
![Flex Pharma cites unspecified “oral tolerability concerns” in halting Phase II trials of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT). [© whitehoune / Fotolia]](https://www.genengnews.com/wp-content/uploads/2018/08/170123090806_1_900x6009916143062-324x160.jpg "Flex Pharma Axes 60% of Workforce, Explores Sale after Halting Phase II Trials in ALS, CMT")
